Compare Stocks

→ top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEMD Aethlon Medical	$1.53 +1.3%	$1.65	$1.35 ▼ $5.00	$4.01M	1.88	8,537 shs	619 shs
BJDX Bluejay Diagnostics	$0.55 -12.7%	$0.75	$0.47 ▼ $13.98	$1.48M	0.85	46,009 shs	12,073 shs
NXGL NEXGEL	$2.33 +5.9%	$2.44	$1.40 ▼ $3.14	$14.52M	0.68	21,120 shs	5,592 shs
VVOS Vivos Therapeutics	$2.57 -3.0%	$4.16	$2.40 ▼ $48.79	$7.02M	7.94	188,566 shs	74,510 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEMD Aethlon Medical	+5.73%	+5.00%	-11.58%	-24.03%	-71.37%
BJDX Bluejay Diagnostics	+0.81%	+9.65%	-22.15%	-25.60%	-90.15%
NXGL NEXGEL	+0.92%	+1.85%	-16.98%	-4.06%	+42.86%
VVOS Vivos Therapeutics	+0.38%	-1.85%	-46.36%	-52.85%	-71.07%

Exposed: 10 CENT Crypto to Explode April 20th? (Ad)

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEMD Aethlon Medical	1.3131 of 5 stars	3.5	3.0	0.0	0.0	1.1	0.0	0.6
BJDX Bluejay Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NXGL NEXGEL	0.1585 of 5 stars	0.0	3.0	0.0	0.0	0.0	3.3	0.0
VVOS Vivos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEMD Aethlon Medical	3.00	Buy	$10.00	553.59% Upside
BJDX Bluejay Diagnostics	2.00	Hold	N/A	N/A
NXGL NEXGEL	N/A	N/A	N/A	N/A
VVOS Vivos Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest VVOS, BJDX, AEMD, and NXGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/4/2024	AEMD Aethlon Medical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $10.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEMD Aethlon Medical	$570K	7.03	N/A	N/A	$6.56 per share	0.23
BJDX Bluejay Diagnostics	$250K	5.92	N/A	N/A	$2.34 per share	0.24
NXGL NEXGEL	$4.09M	3.37	N/A	N/A	$0.90 per share	2.46
VVOS Vivos Therapeutics	$13.80M	0.51	N/A	N/A	$0.22 per share	11.68

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEMD Aethlon Medical	-$12.03M	-$4.99	N/A	N/A	N/A	N/A	-106.28%	-86.60%	6/26/2024 (Estimated)
BJDX Bluejay Diagnostics	-$9.95M	-$9.01	N/A	∞	N/A	N/A	-168.38%	-122.58%	5/8/2024 (Estimated)
NXGL NEXGEL	-$3.16M	-$0.56	N/A	∞	N/A	-77.19%	-49.49%	-30.50%	5/20/2024 (Estimated)
VVOS Vivos Therapeutics	-$13.58M	-$11.05	N/A	∞	N/A	-98.42%	-665.17%	-122.48%	6/13/2024 (Estimated)

Latest VVOS, BJDX, AEMD, and NXGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/1/2024	Q4 2023	NXGL NEXGEL	N/A	-$0.19	-$0.19	-$0.19	N/A	$1.08 million
3/28/2024	Q4 2023	BJDX Bluejay Diagnostics	-$0.68	-$1.78	-$1.10	-$1.78	N/A	N/A
3/28/2024	Q4 2023	VVOS Vivos Therapeutics	N/A	-$3.05	-$3.05	-$3.05	N/A	$3.25 million
2/14/2024	Q3 2024	AEMD Aethlon Medical	-$1.23	-$1.37	-$0.14	-$1.37	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEMD Aethlon Medical	N/A	N/A	N/A	N/A	N/A
BJDX Bluejay Diagnostics	N/A	N/A	N/A	N/A	N/A
NXGL NEXGEL	N/A	N/A	N/A	N/A	N/A
VVOS Vivos Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEMD Aethlon Medical	N/A	3.93	3.93
BJDX Bluejay Diagnostics	N/A	1.82	1.82
NXGL NEXGEL	0.10	1.98	1.46
VVOS Vivos Therapeutics	N/A	0.34	0.34

Ownership

Institutional Ownership

Company	Institutional Ownership
AEMD Aethlon Medical	1.99%
BJDX Bluejay Diagnostics	18.47%
NXGL NEXGEL	2.21%
VVOS Vivos Therapeutics	26.35%

Insider Ownership

Company	Insider Ownership
AEMD Aethlon Medical	4.00%
BJDX Bluejay Diagnostics	47.00%
NXGL NEXGEL	27.15%
VVOS Vivos Therapeutics	9.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AEMD Aethlon Medical	15	2.62 million	2.52 million	No Data
BJDX Bluejay Diagnostics	10	2.69 million	1.43 million	Not Optionable
NXGL NEXGEL	12	6.23 million	4.54 million	Not Optionable
VVOS Vivos Therapeutics	154	2.73 million	2.47 million	Optionable

AEMD, BJDX, NXGL, and VVOS Headlines

Source	Headline
	TELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis americanbankingnews.com - April 15 at 6:20 AM
	Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval proactiveinvestors.com - April 11 at 3:32 PM
	Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices finance.yahoo.com - April 9 at 6:42 PM
	Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices markets.businessinsider.com - April 9 at 1:41 PM
	What's Going On With Vivos Therapeutics Stock? msn.com - April 9 at 1:41 PM
	Medicare to reimburse for Vivos CARE sleep apnea devices msn.com - April 9 at 1:41 PM
	Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursement proactiveinvestors.com - April 9 at 9:31 AM
	Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today? investorplace.com - April 9 at 8:53 AM
	Vivos Therapeutics files to sell 1.73M shares of common stock for holders msn.com - April 9 at 8:41 AM
	Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement finance.yahoo.com - April 9 at 8:41 AM
	Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement globenewswire.com - April 9 at 7:30 AM
	Verve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety Report precisionmedicineonline.com - April 2 at 5:52 PM
	Vivos Therapeutics highlights path to cash flow positivity after FDA clearance proactiveinvestors.com - April 1 at 9:07 AM
	Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations finance.yahoo.com - March 31 at 1:42 PM
	Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript seekingalpha.com - March 30 at 12:38 PM
	Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss marketwatch.com - March 29 at 1:13 AM
	Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update globenewswire.com - March 28 at 4:05 PM
	Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call globenewswire.com - March 28 at 7:30 AM
	Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report benzinga.com - February 22 at 12:09 PM
	Vivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades benzinga.com - February 22 at 7:09 AM
	Vivos Therapeutics secures $4 million through warrant exercise investing.com - February 18 at 12:39 AM
	Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds finance.yahoo.com - February 15 at 9:27 AM
	Vivos Therapeutics sees gross proceeds of $4M from exercise of warrant proactiveinvestors.com - February 15 at 9:13 AM
	Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions finance.yahoo.com - February 12 at 9:45 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aethlon Medical

NASDAQ:AEMD

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.

Bluejay Diagnostics

NASDAQ:BJDX

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

NEXGEL

NASDAQ:NXGL

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Vivos Therapeutics

NASDAQ:VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial